Ansietil

Quick links to important sections

Ansietil

Method of action: Psycholeptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ansietil

Property Description
Active Ingredient Ketazolam
Form Tablet (Oral administration)
Pharmacological Class Benzodiazepine / Anxiolytic
General Purpose Reducing tension and promoting calmness
Origin Synthetic

What Type of Medicine is Ansietil?

Ansietil is a pharmaceutical product whose active ingredient is Ketazolam, and it belongs to the Benzodiazepine class of medicines. It is broadly categorized as a psycholeptic and an anxiolytic, meaning its function is to reduce central nervous system activity. Ketazolam is a synthetic compound derived through chemical processes, and its identity is verified in international reference guides. Ketazolam is specifically a prodrug, which differentiates it by converting into highly potent, long-acting active metabolites, including Diazepam and Nordazepam, after ingestion. This class of medicine is clinically recognized for its calming influence on the central nervous system.


Composition and Physical Form

Ansietil is a single-ingredient formulation delivered primarily for oral administration in the form of a tablet. This structure means the product consists solely of the active ingredient Ketazolam combined with necessary, inactive solid excipients, such as fillers and binders. This formulation is frequently utilized to manage states of persistent emotional stress and generalized restlessness. The tablet format is a standardized delivery mechanism used to ensure the precise, systemic release of the active compound into the body’s circulation.


General Purpose and Core Therapeutic Function

The core therapeutic function of Ansietil is to reduce heightened nervous system activity by enhancing the brain’s natural inhibitory signals, primarily through interaction with GABA receptors. This action underpins its general purpose of mitigating states of chronic tension and unease, contributing to overall relaxation. Ketazolam, via its metabolites, acts as a depressant of the central nervous system, producing an overall tranquilizing effect. This indicates that the medicine is used to effectively ease excessive physical and emotional stress.

Regulatory References

  1. Benzodiazepines - StatPearls - NCBI Bookshelf

What side effects are possible with Ansietil?

Possible Side Effects and Safety Information

Ansietil (Ketazolam) exhibits a safety profile aligned with the benzodiazepine class, with adverse reactions formally categorized by frequency and the body systems affected in regulatory documents.

Adverse Reaction Classifications

The most commonly documented adverse reactions, which often occur at the beginning of treatment and may diminish with continued use, are related to Central Nervous System (CNS) depression. These include drowsiness, fatigue, confusion, vertigo, muscle weakness, and ataxia (lack of coordination). Less common effects reported in official documents involve gastrointestinal disorders, skin reactions, and accommodative disorders.

Regulatory agencies group these effects by System-Organ Class (SOC), identifying impacts on the Nervous System, Psychiatric Disorders, and Musculoskeletal system, among others.

Serious Adverse Risks and Constraints

Official labeling documents emphasize several serious risks, including the potential for Abuse, Misuse, and Addiction. The development of Physical Dependence is a recognized risk, and abrupt discontinuation may lead to severe Withdrawal Reactions. Furthermore, a significant risk is the potential for severe Respiratory Depression and profound sedation, particularly when the medicine is used at the same time as opioids or other CNS depressants.

Safety is also defined by duration and dose-related patterns: the risk of tolerance and dependence is documented to increase with longer treatment duration and higher daily doses.

Specific Population Safety Constraints apply. For instance, older adults are at an increased risk of CNS effects, which may elevate the risk of falls. The medicine is formally contraindicated in patients with conditions such as severe hepatic insufficiency or severe respiratory insufficiency, as stated in regulatory prescribing information.

Overdose and Emergency Response

Overdose: When to Seek Help

The official overdose profile is primarily defined by Central Nervous System (CNS) depression, which can range in severity. An isolated oral overdose typically presents with symptoms such as drowsiness, slurred speech, and ataxia (impaired coordination), often with vital signs remaining close to normal. In these situations, severe toxicity is rare, but all suspected overdoses require medical evaluation.

Documented Overdose Manifestations

Severity Level Manifestations (Signs and Symptoms)
Mild/Moderate Drowsiness, slurred speech, ataxia, confusion, altered mental status.
Severe Toxicity Stupor, coma, profound respiratory depression, and potentially death.

Urgent Medical Action

Immediate medical help must be sought if the overdose results in severe toxicity, specifically a stuporous or comatose state, or if there is any evidence of respiratory compromise (difficulty breathing or slow, shallow breaths). The risk of severe, life-threatening outcomes, including respiratory arrest, is significantly increased when the drug is taken in combination with other substances, such as alcohol or opioids.

Treatment is predominantly supportive care, which may include immediate airway management and mechanical ventilation in cases of severe respiratory depression. While an antidote (Flumazenil) exists to reverse sedation, its use is carefully restricted due to associated risks.

Therapeutic Uses of Ansietil

What Ansietil Treats: Main Uses and Benefits

Ansietil is generally considered relevant in conditions characterized by heightened emotional and psychological distress; it is applied to help address the symptomatic cluster of persistent worry, apprehension, and irritability. It is used in contexts where chronic tension and unease create noticeable interference with daily stability. This medication is commonly used to help with symptoms related to psychological tension and generalized discomfort. The therapeutic benefit is to offer symptomatic relief that helps patients cope more steadily with these difficult emotional episodes.

This medication helps address the physical component of anxiety by alleviating excessive physical tension and generalized restlessness. Furthermore, it is relevant for symptomatic relief across conditions involving involuntary muscle contractions, such as neurological spasticity. The types of conditions for which this medication is commonly used include those involving episodic or fluctuating manifestations of anxiety, symptoms of increased neurological or muscular activity, and acute or disruptive episodes of tension.

“The medication may assist with maintaining functional stability during episodes of heightened discomfort.”

Ansietil is applied in clinical settings marked by the sudden escalation of symptoms, such as acute tension states. It is used during phases where the patient experiences heightened agitation and discomfort, and supports patients during episodes of heightened discomfort. This temporary assistance supports general well-being during symptomatic phases.

Quick Fact: Symptom Management
This medication is applied in situations where symptoms of psychological tension and physical restlessness create noticeable physiological strain.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ansietil (Ketazolam)

This information is strictly based on regulatory documentation for the active ingredient Ketazolam, which is a benzodiazepine derivative and the recognized active substance in Ansietil in certain markets. Ketazolam is not approved for use in the United States.


Populations with Official Restrictions

Classification Population Group Regulatory Status
Contraindicated Known hypersensitivity to Ketazolam or other benzodiazepines. Prohibited
Contraindicated Patients with severe respiratory insufficiency. Prohibited
Contraindicated Patients with severe hepatic insufficiency. Prohibited
Contraindicated Patients with sleep apnea syndrome. Prohibited
Contraindicated Patients with myasthenia gravis. Prohibited
Use Requires Special Consideration Older adults Requires dose reduction and monitoring
Use Requires Special Consideration Patients with renal impairment or mild to moderate hepatic impairment. Requires dose adjustment and monitoring
Use Requires Special Consideration Pediatric patients Safety and effectiveness are not widely established; use only if considered essential.
Physiological State Pregnancy and Lactation Not recommended, as the drug can cross the placental barrier and pass into breast milk.

Connection to the Overall Eligibility Profile

Regulatory documents define who cannot use Ketazolam through several absolute contraindications, primarily centered on patient safety risks related to neuromuscular and respiratory function, such as myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome. Further significant restrictions are imposed for patients with severe hepatic impairment, while other populations, including older adults and those with renal impairment, require cautious use and specialized dose management. The medicine is not officially recommended for use during pregnancy or lactation due to documented transfer to the fetus/infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ansietil (Ketazolam) structures its documented interaction patterns based on two primary mechanisms: the additive effect on the central nervous system (CNS) and alterations to metabolic clearance.

Official Interaction Statements

  • Central Nervous System (CNS) Depressants: Co-administration with other CNS depressants, including Opioids, Barbiturates, and Alcohol, is officially documented to result in an additive depressant effect. This pharmacodynamic interaction is formally linked to regulatory restrictions and an FDA Boxed Warning due to the risk of profound sedation and respiratory depression.
  • CYP3A Inhibitors (Contraindicated Combinations): Co-administration with strong inhibitors of the Cytochrome P450 3A (CYP3A) enzyme pathway, such as Ketoconazole and Itraconazole, is officially documented to decrease the clearance of the drug's active metabolites. This pharmacokinetic interaction leads to increased and prolonged plasma concentrations and defines certain contraindicated combinations.
  • CYP3A Inducers: Substances like Rifampicin are documented to increase metabolic clearance of the active compound, which may potentially reduce systemic exposure.
  • Food/Substance Interactions: Consumption of Alcohol significantly increases the risk and severity of CNS depression. Grapefruit products are documented to increase plasma levels of benzodiazepines by inhibiting the CYP3A metabolic pathway.
  • Population Notes: Interactions are noted in official labeling to carry a heightened risk of adverse outcomes in the elderly and in patients with severe hepatic impairment, due to increased susceptibility to profound sedation and reduced clearance.

These official statements define the regulatory constraints on Ansietil's co-administration with other medicines and substances. The primary focus of the regulatory profile is on controlling the risk stemming from additive CNS effects and preventing accumulation caused by reduced metabolic clearance.

Mechanism of Action

Modulating the CNS's Main Inhibitory Pathway

The core mechanism of Ansietil, through its active forms, is the Positive Allosteric Modulation (PAM) of the GABA-A receptor, the brain's principal inhibitory target. This action amplifies the efficacy of the neurotransmitter GABA, increasing the inflow of negative chloride ions ( Cl^-) into nerve cells. This physiological event, known as hyperpolarization, contributes to the stabilization of the neural membrane and dampens overall neuronal excitability.

Mechanism for Sustained Physiological Effect

Ansietil is administered as the parent molecule, a prodrug that undergoes metabolic conversion into active, long-acting forms, primarily Nordazepam. These metabolites act on the same GABA-A receptor. Their prolonged presence ensures the positive allosteric modulation mechanism remains engaged over an extended period. This sequential activity provides a sustained dampening of neuronal excitability that characterizes the resulting physiological state, specifically modulating circuits within the Limbic System and centrally mediated muscle tone.

Dosage and Administration Information

Ansietil, whose active substance is Ketazolam, is designated exclusively for oral administration in the form of a capsule. Dosage ranges, frequency, and duration limits characterize the administration of the medicine.


Standard Dosage and Timing

The standard adult dosing regimen is administered once daily. The daily dose range is 15 mg to 75 mg, with a typical mean daily dose being 30 mg. Treatment is initiated at the lowest effective dose. The medication is preferably taken in the evening before going to bed, and should be ingested with some liquid. This specific timing aligns with the drug's intended pattern of activity.


Duration and Special Populations

Treatment with Ketazolam is time-bound and is maintained for the shortest possible period. For symptomatic tension, the total duration, which includes the period of gradual discontinuation, should not exceed 8 to 12 weeks.

Specific dosing rules apply to certain groups. The medicine is not to be used in patients aged below 18 years. Additionally, a reduced dose is required for older adults, weakened patients, and those with chronic respiratory insufficiency, ensuring dose control across all treatment phases.

Recent Clinical Evidence

The research available for Ansietil (Ketazolam) has explored outcomes related to two distinct clinical situations: exploring outcomes related to anxiety symptoms and exploring outcomes related to involuntary muscle contractions. This overview summarizes the structure of the evidence reported in controlled clinical trials and scientific literature, describing what was studied and what remains uncertain.


Evidence for use in Symptomatic Anxiety and Emotional Distress

Studies exploring anxiety symptoms often used Randomized Controlled Trials (RCTs) and Double-blind, Placebo-controlled studies to evaluate Ansietil in specific cohorts of adult outpatients with generalized anxiety disorder (GAD) and psychoneurotic anxiety. Researchers monitored outcomes related to symptom intensity using standardized scales like the Hamilton Anxiety Scale (HAM-A). Research examined changes measured during the study period, including comparisons against placebo or an active comparator. However, follow-up durations were limited in many core studies, typically assessing outcomes only over a short-term period of approximately four weeks, limiting information for long-term outcomes.


Evidence for use in Neurologic Spasticity and Involuntary Muscle Contractions

Research has also explored Ketazolam in conditions characterized by physical symptoms, specifically neurologic spasticity. These studies often used Crossover Trials focusing on specific populations, including patients with Multiple Sclerosis (MS) or spasticity following a Stroke. Trials monitored outcomes related to physical discomfort using clinical assessments and objective methods like Electromyography (EMG) recording. Evidence for this application is limited, as the sample sizes were modest, and the duration of research was confined to short-term assessment periods, meaning sustained measurements are limited.


Evidence Gaps and Areas of Uncertainty

The research landscape presents several areas where data remain limited. The primary research base focused overwhelmingly on the adult outpatient population, and data for certain groups, such as children or older adults, remain insufficient. Furthermore, follow-up durations were limited in many pivotal trials, restricting insight into long-term outcomes and the durability of reported effects. The research mainly consists of older publications, and comparative evidence is limited regarding other treatment options.

Frequently Asked Questions (FAQ)

Common questions about Ansietil (FAQ)

Q: How long does one dose of Ansietil typically last in the body?

A: Official product information notes that Ansietil is a prodrug, meaning it converts into active substances, such as Nordazepam, in the body. These active forms have long half-lives, which ensures the medication provides a sustained period of activity after each dose.

Q: Is Ansietil used for general anxiety or only specific types?

A: Official product information notes that the drug’s active substance addresses symptomatic anxiety and emotional distress. Research supporting its use has often focused on specific conditions, such as Generalized Anxiety Disorder (GAD) and psychoneurotic anxiety.

Q: Does Ansietil have a 'rebound' anxiety effect when it wears off?

A: Regulatory warnings indicate that stopping the medication suddenly or reducing the dose too quickly can lead to severe withdrawal reactions. The label documents that withdrawal may include symptoms like increased anxiety.

Q: Can Ansietil be prescribed for teenagers or children?

A: Official product information advises that this medicine is not for use in patients under 18 years of age. This is because the safety and effectiveness of the medication have not been widely established for pediatric populations.

Q: Are there any long-term effects of taking Ansietil for an extended period?

A: Regulatory documents explicitly warn that the risk of developing tolerance and physical or psychological dependence is documented to increase with a longer duration of treatment, particularly beyond the typical limit of 8 to 12 weeks. This risk is a primary factor documented in regulatory guidance regarding limiting the duration of treatment.

Q: Can Ansietil cause stomach issues or nausea?

A: According to official prescribing information, less common side effects that have been reported include gastrointestinal disorders, which may involve symptoms such as nausea.

Q: What's the difference between Ansietil and a common antidepressant?

A: Ansietil belongs to the Benzodiazepine class, which acts as an anxiolytic and central nervous system depressant. It works by specifically enhancing the effects of the brain's main calming signal, GABA. Antidepressants generally operate through mechanisms related to different neurotransmitter pathways.

Q: How does Ansietil affect the brain chemicals?

A: The mechanism of Ansietil's action involves amplifying the effects of the neurotransmitter GABA, which is the brain's principal inhibitory chemical. This action increases the flow of negative chloride ions into nerve cells, helping to stabilize the neural membrane and reduce overall brain excitability.

Q: Do you build a tolerance to Ansietil over time?

A: Official safety documents indicate that the risk of developing tolerance is documented to increase. This risk is particularly associated with taking the medication for longer periods or at higher daily doses.

Q: What is the mechanism of action of Ansietil?

A: The core mechanism involves the positive allosteric modulation of the GABA-A receptor. This action enhances the natural inhibitory signals in the brain, which contributes to the drug's calming and muscle-relaxing effects.

Q: What are some rare but serious side effects of Ansietil?

A: Serious risks highlighted in official warnings include the potential for Abuse, Misuse, and Addiction. Other serious risks documented are profound sedation, severe respiratory depression, and severe withdrawal reactions if the medication is stopped suddenly.

Q: How does the half-life of Ansietil influence its dosing schedule?

A: Because the drug converts into long-acting metabolites, which remain in the body for an extended time, a sustained effect is provided. This allows the medication to be administered effectively as a once-daily dose.

Q: Can Ansietil cause difficulties with memory or concentration?

A: Adverse reactions related to Central Nervous System (CNS) depression are common, and these include confusion. This general effect on the CNS may potentially impact concentration and other cognitive functions.

Q: Is it normal to have vivid dreams when starting Ansietil?

A: Abnormal dreams are reported as a potential adverse reaction under the Nervous System category in official documents. Changes to the sleep cycle or dreams can be reported as part of the drug's effect on the central nervous system.

Q: Are there any foods or drinks to avoid while on Ansietil?

A: Regulatory documents warn specifically against the consumption of Alcohol, as it significantly increases the risk and severity of CNS depression. Regulatory documents caution about Grapefruit products, which are documented to increase the plasma levels of similar benzodiazepine drugs.

Q: Does Ansietil affect your ability to drive or operate machinery?

A: Official warnings caution that this drug can cause drowsiness, fatigue, and muscle weakness. Due to the potential for impaired coordination and mental state, official information recommends caution regarding driving or operating potentially dangerous machinery until the effects of the medication are known.

Q: Can taking Ansietil cause changes in mood that are not related to anxiety?

A: Adverse events reported in official documents include effects grouped under Psychiatric Disorders. While Ansietil is an anxiolytic, the documentation indicates the potential for other mood-related changes to be reported.

Q: How important is it to take Ansietil at the exact same time every day?

A: The standard regimen involves once-daily administration, and it is preferably taken in the evening before bed. Consistent administration is important to maintain stable drug levels and align with the intended pattern of sustained activity.

Q: What evidence is there regarding Ansietil's effectiveness in panic attacks?

A: The available research overview focuses on outcomes related to symptomatic anxiety, specifically Generalized Anxiety Disorder, and neurologic spasticity. The effectiveness of the drug specifically for panic attacks is not documented in the current overview of clinical evidence.

Q: Does Ansietil interact badly with herbal supplements like St. John's Wort?

A: The label warns about interactions with substances that induce the CYP3A enzyme pathway. Herbal supplements known to act as enzyme inducers, like St. John’s Wort, may increase the clearance of the drug, which could potentially reduce its effectiveness.

How should Ansietil be stored and disposed of?

How to Store and Dispose of Ansietil?

Ansietil (Ketazolam) must be stored according to official regulatory specifications to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (typically 20 C to 25 C).
Protection The tablets must be protected from light and excessive moisture.
Container Keep the medicine in its original container, tightly closed.
Handling Do not freeze the tablets.

Child-Safety and Disposal

The medication must be stored out of the sight and reach of children and kept in a secured location. For disposal, unused or expired Ansietil should not be thrown into household waste or wastewater. Consult a pharmacist or local waste management program for instructions on how to properly dispose of the medicine according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ansietil found in:

A-Z Index: